Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Barry Callebaut H1 Profit Declines; Backs Growth Forecast - Quick Facts

Barry Callebaut AG (BYCBF.PK), a Swiss manufacturer of cocoa and chocolate products, on Monday said its first-half net profit declined 18 percent to 121.8 million Swiss Francs from 148.6 million francs last year due to higher operating expenses as well as higher financing costs related to the bond placement in summer 2011. In local currencies, profit fell 11.3 percent.

Sales volume grew 6.7 percent to 699,058 tonnes and again outperformed the worldwide chocolate confectionery market, the company said. Sales revenue increased 3 percent to 2.48 billion francs from last year's 2.40 billion francs. Sales grew 10.4 percent in local currencies.

The company noted that all regions and product groups contributed to the volume growth, which rebounded strongly in the second quarter.

CEO Juergen Steinemann said, "After an anticipated slow start in Q1, we regained momentum in Q2, in all Regions and across all Product Groups. Once again, we outpaced the global chocolate market. Several major new partnership deals were signed, confirming an important part of our business model. In the last six months, we initiated selective investments in our future growth. This temporarily affected our bottom-line results."

Looking ahead, the company said it is confident of reaching mid-term financial targets, even though the economic environment in Western Europe and North America remains fragile.

The company's four-year growth targets for 2009/10-2012/13 include on average 6-8 percent volume growth and average EBIT growth in local currencies at least in line with volume growth.

Register
To receive FREE breaking news email alerts for Barry Callebaut and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Pharmaceutical giant Pfizer, Inc., which was aspiring to buy British drug maker AstraZeneca Plc, reported Tuesday a profit for the second quarter that plunged 79 percent from last year, which reflected hefty gains from animal health business sales. Total revenues declined 2 percent, as it continued to be hurt by generic competition for major drugs. Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.